Trial Profile
Therapeutic Drug Monitoring of Sunitinib and Pazopanib in Advanced or Metastatic Renal Cell Carcinoma
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 13 Jan 2021
Price :
$35
*
At a glance
- Drugs Pazopanib (Primary) ; Sunitinib (Primary)
- Indications Renal cell carcinoma
- Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
- Acronyms SUP-R
- 11 Jan 2021 Status changed from active, no longer recruiting to completed.
- 14 Mar 2019 Status changed from recruiting to active, no longer recruiting.
- 07 Aug 2017 Planned End Date changed from 1 Apr 2020 to 1 Jun 2021.